Venture Global, Inc. Receives Notice of Lawsuit: A Heartfelt Examination of the Legal Alert Issued by Levi & Korsinsky

Suffering a Loss on Venture Global, Inc. (VG) Investment: Understanding Your Recovery Options under Federal Securities Laws Investing in the stock market can be an exciting and rewarding experience, but it also comes with inherent risks. If you have recently experienced a loss on your investment in Venture Global, Inc. (VG), you may be feeling…

Read More

TC Energy’s Heartwarming Milestone: South Bow’s $7.9 Billion Notes Offering for Liquids Pipelines Spinoff Successfully Closed

TC Energy Corporation Closes Notes Offering for Spinoff of Liquids Pipelines Business Setting the Stage for a Major Transaction Calgary, Alberta, Aug. 28, 2024 (GLOBE NEWSWIRE) — TC Energy Corporation (TSX, NYSE: TRP) announced today that South Bow Corporation (South Bow) has closed a notes offering of approximately $7.9 billion Canadian-dollar equivalent in aggregate principal…

Read More

60-Degrees Pharma’s Tafenoquine: IRB Green-Lights Phase II Trial for Chronic Babesiosis Treatment

Exciting News in the World of Medical Research: An Open-Label Study on Tafenoquine for Chronic Babesiosis In the ever-evolving landscape of medical research, there’s always something new and intriguing on the horizon. Today, we’re going to delve into the world of babesiosis and an upcoming open-label study involving the drug tafenoquine. So, grab a cup…

Read More

Breaking News: Jackpot Digital Strikes Gold with Debt Renegotiation – Saves CDN$3.75 Million!

Welcome to the Jackpot Digital Inc. Blog! A Fifth Amendment Agreement for Jackpot Digital Inc. Vancouver, British Columbia–(Newsfile Corp. – September 23, 2024) Jackpot Digital Inc. (TSXV: JJ) (TSXV: JJ.WT.B) (TSXV: JJ.WT.C) (OTCQB: JPOTF) (FSE: LVH3) (the “Company” or “Jackpot”) is pleased to announce that further to its news release dated July 10, 2023, the…

Read More

Arch Biopartners Receives Health Canada’s Green Light for Phase II Trial of Cilastatin to Treat Drug-Induced Acute Kidney Injury

Arch Biopartners Receives No Objection Letter from Health Canada for PONTiAK Trial Toronto, Canada, February 18, 2025 – Arch Biopartners Inc. (ARCH or the “Company”), a clinical stage biotechnology company, is thrilled to announce that the clinical team leading the upcoming investigator-led trial, titled “Prevention Of NephroToxin Induced Acute Kidney Injury with Cilastatin” (PONTiAK), has…

Read More

SBI Venture Capital to Introduce USDC Support in Japan: A New Milestone in Digital Currency Adoption

SBI VC Trade’s Completion of USDC Registration: A New Era for Stablecoin Transactions SBI Virtual Currencies (SBI VC Trade), a Japanese cryptocurrency exchange and a subsidiary of SBI Holdings, recently announced the successful completion of its initial registration process with the Japanese Financial Services Agency (FSA) for stablecoin transactions. This registration marks a significant milestone…

Read More